Interestingly, those patients seem to be more sensitive to another BCL-2 inhibitor, Obatoclax mesylate, which was demonstrated to show only modest efficacy in the treatment of hematological malignancies including AML, and have not been approved for clinical use yet [53]. This evidence concerns the gene BCL2 and acute myeloid leukemia.